A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...
Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...
Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a study found.
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination ...
Discover the groundbreaking medical trial offering new hope for autoimmune diseases and the first courageous patient behind ...
A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS, but it ...
Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for disease prevention and repair. The Multiple Sclerosis International Federation ...
France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...